Report of Foreign Issuer (6-k)
January 08 2018 - 4:07PM
Edgar (US Regulatory)
United
States
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the Month of January, 2018
Commission File Number: 001-35892
GW
PHARMACEUTICALS PLC
(Translation of registrant’s name
into English)
Sovereign
House
Vision
Park
Histon
Cambridge
CB24 9BZ
United
Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Notification of Interests Of Directors,
Officers And Connected Persons
GW Pharmaceuticals plc (the “Company”)
hereby provides notification that on January 3, 2018 the Company granted the following awards to Directors over the Company’s
American Depositary Shares (“ADSs”) in the form of options (“Awards”) under the GW Pharmaceuticals plc
Long-Term Incentive Plan 2017, which was approved by shareholders on March 14, 2017.
These Awards are made in
accordance with the Company’s compensation policy approved by shareholders at the Annual General meeting in February
2015 and are made following completion of a comprehensive peer-group benchmarking analysis by the Company’s
independent remuneration advisers Willis Towers Watson.
Awards to non-executive Directors:
Name
|
Market Priced Options
To acquire ADSs
|
Restricted Stock Units granted
To acquire ADSs
|
James Noble
|
1,473
|
895
|
Thomas Lynch
|
1,473
|
895
|
Cabot Brown
|
1,473
|
895
|
Alicia Secor
|
2,945
|
895
|
Catherine Mackey
|
2,945
|
895
|
William Waldegrave
|
2,945
|
895
|
The market-priced options have an exercise
price equivalent to the market price at market close on the last trading day prior to the grant of $134.09 per ADS. These options
will vest on the third anniversary of the date of grant.
Alicia Secor, Catherine Mackey and William
Waldegrave joined the GW Board on December 21, 2017. Consequently, their Awards include 1,472 Market-priced options which represent
a one-time only grant of Awards upon joining the Board.
The restricted stock units, have an exercise
price equivalent to the nominal value of the twelve ordinary shares that underlie each of the Company’s ADSs, being 0.016
dollars per ADS. One third of these units will vest on each anniversary of the grant over a three-year vesting period.
For further information, please contact:
GW Pharmaceuticals PLC
|
+44 (0)1980 557 000
|
Adam George, Company Secretary
|
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
GW Pharmaceuticals plc
|
|
|
|
|
By:
|
/s/ Adam George
|
|
Name:
|
Adam George
|
|
Title:
|
Company Secretary
|
|
|
|
Date: January 8, 2018
|
|
|